Visit www.fda.gov/medwatch, or call 1-800-FDA-1088
Participants in the semaglutide group achieved a weight loss of at least 5%, 10%, or 15%, and improvements in secondary endpoints, such as waist circumference, blood pressure, and lipid levels, compared to the placebo group
The US Food and Drug Administration (FDA) has approved Wegovy to: Reduce body weight and support long-term weight loss in people with obesity or with overweight and a weight-related health condition, such as type 2 diabetes or sleep apnea Reduce the risk of experiencing a major cardiovascular event , such as heart attack, stroke, or death, in people with heart disease and obesity or overweight Typically, healthcare providers prescribe a starting dose of 0.25 mg weekly
Factors Affecting Fatigue Levels The incidence of Semaglutide tiredness can differ based on the administration method
Allowing the medication to reach room temperature before injecting also helps